AACR 2024 | Updated results of the LINKER-MM1 trial: linvoseltamab in R/R multiple myeloma

Sundar Jagannath, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses updated results from the LINKER-MM1 trial (NCT03761108) evaluating the use of linvoseltamab for treating relapsed/refractory (R/R) multiple myeloma (MM). A large proportion of patients enrolled had failed three or more prior lines of therapy and were triple-class refractory. Despite this high-risk demographic, linvoseltamab showed a high overall response rate (ORR) and complete response (CR) rate. The agent was well tolerated, and the most common side effects were those typical for bispecific antibodies, including manageable cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), hematological toxicity, and infection. The infection rates significantly decreased after six months due to the reduced frequency dosing schedule used at this stage. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.